Acute panuveitis after COVID-19 mRNA booster vaccination following cataract surgery

Timothy-Paul H. Kung \textsuperscript{a}, Charles Zhang \textsuperscript{b, *}, Sandra F. Sieminski \textsuperscript{b}

\textsuperscript{a} Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, 955 Main St, Buffalo, NY, 14203, USA
\textsuperscript{b} Department of Ophthalmology, Ross Eye Institute, University at Buffalo, 1176 Main St, Buffalo, NY, 14209, USA

\textbf{ARTICLE INFO}

\textbf{Keywords:}
COVID-19
Panuveitis
mRNA vaccine
BNT162b2
Cataract extraction and intraocular lens implantation
Postoperative endophthalmitis

\textbf{ABSTRACT}

\textbf{Purpose:} To report a case of presumed COVID-19 Pfizer third dose (booster) vaccination leading to severe panuveitis mimicking acute endophthalmitis in the early postoperative period following routine cataract extraction and intraocular lens implantation.

\textbf{Observations:} A 68-year-old female with mild refractive error who previously received 2 doses of the BNT162b2 vaccine underwent routine cataract extraction and intraocular lens implantation in the right eye. On postoperative day (POD) 2 the patient received her BNT162b2 booster vaccination. On POD 3 the patient’s vision was hand motion at face with photophobia. Anterior segment examination was significant for 2+ conjunctival injection, mild stromal edema, 4+ cell and flare with trace hypopyon, and 4+ anterior vitreous cell without any wound leak. Subsequent Gram staining, culture for aerobic and anaerobic bacteria, KOH preparation, and PCR testing for infectious organisms were also obtained, all of which were found to be negative. ESR and CRP values were also negative. The patient was started on intravitreal injections of vancomycin and ceftazidime, as well as oral moxifloxacin, fortified vancomycin and tobramycin drops, prednisolone acetate 1%, and atropine 1%. On POD 5 the patient reported significant improvement of her vision and was found to have 20/80 vision. On POD 12 her vision improved to 20/25, and improved further on POD 19 to 20/20 vision with a completely normal examination. Cultures remained negative throughout the entire course.

\textbf{Conclusions and importance:} This is the first report to suggest a possible association between the BNT162b2 booster vaccination and development of acute panuveitis in the postoperative period following routine cataract extraction and intraocular lens implantation. This condition may mimic acute bacterial postoperative endophthalmitis and may portend a more favorable prognosis, but the authors believe such cases should nonetheless be treated aggressively as presumed infection.

\section{1. Introduction}

Since being identified in 2019, the SARS-CoV-2 virus has been responsible for an unprecedented global pandemic and public health emergency. In response to the initial spread of the virus, efforts to quickly develop a suitable vaccine began, and in December 2020 the Food and Drug Administration issued an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 (BNT162b2) and Moderna COVID-19 vaccines.\textsuperscript{1}

As vaccination rates increase, greater attention is now being paid to the adverse effects of these vaccines. These typically include systemic and inflammatory effects such as headache, fatigue, chills, diarrhea, fever, arthralgia, myalgia, and nausea.\textsuperscript{2–4} Specific ocular adverse effects have also been associated with the BNT162b2 vaccine\textsuperscript{5} including corneal graft rejection,\textsuperscript{6–8} anterior uveitis,\textsuperscript{9} panuveitis,\textsuperscript{10–13} posterior uveitis,\textsuperscript{14} central serous chorioretinopathy,\textsuperscript{15} and abducens nerve palsy.\textsuperscript{16} Additionally, data suggest patients may experience increased systemic adverse effects\textsuperscript{3–17} as well as increased organ-specific effects after additional doses of the vaccine as compared to after the first dose.\textsuperscript{18–20}

We present a case of presumed COVID-19 Pfizer third dose (booster) vaccination leading to severe panuveitis mimicking acute endophthalmitis in the early postoperative period following routine cataract extraction and intraocular lens implantation (CEIOL).
2. Case report

A 68-year-old Caucasian female patient was referred to the ophthalmology clinic for cataract evaluation. Past ocular history was negative except for mild myopic refractive error. Past medical history was significant for nephrectomy secondary to a perinephric abscess in her youth as well as blunt force trauma to the right orbit. The patient was otherwise healthy with no history of systemic disease and not taking any medications. The patient denied any COVID-19 symptoms since the start of the pandemic and had received 2 doses of the BNT162b2 vaccine prior to the operation. She also reported a negative nucleic acid amplification test result (Hologic Aptima® SARS-CoV-2 assay) five days prior to her scheduled surgery.

Preoperatively, she had a best corrected visual acuity of 20/70 and 20/50 in her right and left eye, respectively. Pupils were equally round and reactive. Intraocular pressure (IOP) was 23 and 18 mm Hg in both eyes. Anterior segment examination with slit lamp was significant for 3+ cortical, 2+ nuclear sclerotic, and 1+ posterior subcapsular cataracts in both eyes. Fundus examination was significant for mild asymmetry of the cup to disc ratio at 0.4 and 0.6 for the right and left eyes, respectively. The risk and benefits of cataract surgery were explained to the patient and she elected to proceed with her right eye first.

Intraoperatively, it was noted that she had 1-2 clock hours of zonular dialysis presumably due to her prior right orbital trauma. Thus, after nuclear removal, a capsular tension ring was placed prior to insertion of an SN60WF monofocal lens in the lens bag. No signs of prolapsed vitreous were noted intraoperatively including by triamcinolone staining and miotic intracameral injection at the end of the case.

On postoperative day (POD) 1, the patient reported excellent vision and no pain. She was found to have 20/20 vision in the right eye with a normal IOP. The cornea was clear with only trace cell in the anterior chamber (AC) and the intraocular lens was well centered within the bag. There was no vitreous cell.

On the morning of POD 2 the patient elected to receive her BNT162b2 booster. By night, she reported that she had started to develop systemic symptoms including mild fever, joint pain, and headache. She also noted that her vision in her operated eye was mildly blurred. The patient attributed this to being tired and went to bed after taking acetaminophen.

On the morning of POD 3 the patient awoke with fever, body aches, and poor vision, and was seen emergently in the clinic. She reported a significant decrease in vision with photophobia, but denied any pain. Her vision was found to be hand motion at face with normal IOP. Anterior segment examination was significant for 2+ conjunctival injection, mild stromal edema, 4+ cell and flare with trace hypopyon, and 4+ anterior vitreous cell without any wound leak. No view to the posterior pole could be obtained and a B-scan demonstrated an attached retina with dense vitreous cell (Fig. 1). Due to the high suspicion of acute postoperative endophthalmitis, an intravitreal tap was attempted using a 25-gauge needle on a 3-mL syringe but was unsuccessful. An anterior chamber paracentesis was performed using a 30-gauge needle and 150 μL of fluid was obtained for culture. Subsequent Gram staining, culture for aerobic and anaerobic bacteria, KOH preparation, and PCR testing for infectious organisms were also obtained, all of which were found to be negative. ESR and CRP values were also negative. One mg of vancomycin and 2 mg of ceftazidime each in 100 μL were injected intra- vitreally. She was also started on oral moxifloxacin 400 mg daily, fortified vancomycin and tobramycin drops four times a day, prednisolone acetate 1% four times a day, and atropine 1% twice a day.

On POD 5 the patient reported significant improvement of her vision, photophobia and systemic symptoms and was found to have 20/80 vision. Her anterior segment examination had improved to 1+ injection, 1+ punctate epithelial erosions, 1–2+ Descemet’s folds, 2+ mixed cells in the AC without hypopyon or fibrin, and 2+ vitreous cell. On POD 12 the patient reported complete improvement of her vision with no symptoms. Her vision had improved to 20/25 with a normal IOP. Her examination was significant only for trace injection, few residual stellate keratic precipitates, and trace cell with a normal posterior pole. On POD 19, she achieved 20/20 vision with a completely normal examination. Dilated fundus examination was also normal. Cultures remained negative throughout the entire course.

3. Discussion

We present a case of acute panuveitis which developed shortly after receiving a booster immunization with the Pfizer-BioNTech mRNA COVID-19 vaccine during the postoperative period that was treated as acute postoperative endophthalmitis. To the best of our knowledge, this is the first report of panuveitis after a booster dose of mRNA COVID-19 vaccine postoperatively after cataract surgery.

Although the patient presented in the classic window for acute postoperative bacterial endophthalmitis, several characteristics in the clinical course make us consider immunization as the primary contributor to the patient’s presentation: Firstly, the temporal association between the immunization, the patient’s systemic symptoms, and subsequent intraocular inflammation; secondly, the rapid visual recovery from hand motion vision to 20/80 in less than 48 hours after the tap and injection; thirdly, the eventual recovery to better than 20/40 vision, which occurs in less than 13–33% of cases of bacterial endophthalmitis;21–23, and finally, although a vitreous tap could not be successfully obtained, the absence of bacterial infection.

There has been increasing evidence that uveitis may be associated with vaccinations. A comprehensive systematic review compiling reports of vaccine-related uveitis identified 289 cases of uveitis from 1984 to 2015 after a variety of vaccinations.24,25 These included the hepatitis B virus, human papillomavirus, influenza, Bacille Calmette-Guerin, measles-mumps-rubella, varicella virus, and hepatitis A vaccines. Additionally, of the patients whose gender was recorded, more than two-thirds were female.

Recently, an increasing number of uveitis cases have also been reported following vaccination with the BNT162b2 vaccine. One retrospective study found twenty-one cases of mild-to-moderate anterior uveitis within 7.5 ± 7.3 days following either the first or second dose of the BNT162b2 vaccine.12 A study also reported two cases of multiple evanescent white dot syndrome after the BNT162b2 vaccine.26 Furthermore, a study of 686 patients with autoimmune inflammatory rheumatic diseases receiving two doses of the BNT162b2 vaccine
reported two cases of uveitis within 2-6 weeks of receiving the second dose.27 Another report identified a patient who developed panuveitis 3 days after a second dose of the BNT162b2 vaccine.30

Determining serum or ocular markers associated with vaccine-related uveitis may help to determine the pathophysiology of uveitis after administration of the BNT162b2 vaccine. A recent study has identified a signature serum cytokine profile after administration of the BNT162b2 vaccine, and found increases in IL-15, IFN-γ, and IP-10/CXCL10 after the first dose with a subsequent rise in TNF-α and IL-6 after the second dose.28 The presence of IP-10/CXCL10, IL-6, and TNF-α have been associated with uveitis in both murine and human models. Increased IP-10/CXCL10 levels have been found in the aqueous humor28,30 and tears31 of patients with active uveitis. Additionally, elevated levels of IL-6 in the vitreous fluid have been found in patients with uveitis,32,33 with IL-6 inhibition demonstrating improvement in uveitis symptoms.34,35 Elevated levels of TNF-α have also been found in the ocular fluid of patients with uveitis,36 with anti-TNF-α treatment showing effectiveness in curtailing inflammation in uveitis patients.37

IL-1 is known to cause many of the same systemic side effects seen after vaccination with BNT162b2, such as fever, chills, headache, nausea, vomiting, and myalgia.38,42 The development of autoimmune uveitis has also been linked to IL-1 levels in patients. Increased secretion of IL-1β in the retina by neutrophils, macrophages, and dendritic cells is present in murine experimental autoimmune uveitis.43 Anti-IL-1 antibody treatments such as anakinra and canakinumab have also been successful in treating uveitis in humans.44,45

Although previously reported cases of uveitis tended to occur 3 or more days after vaccination,40,46 the shorter temporal relationship in our patient may be compounded by the post-inflammatory response after CEIOL. Cataract surgery represents a form of trauma to the eye, which has been demonstrated to cause postoperative inflammation.47,48 One of the proposed mechanisms is due to weakening of the blood aqueous barrier from increased postoperative levels of intraocular prostaglandin E2 and F2α.49,50 Such factors may have led to expedition of the systemic cytokine to penetrate the intraocular milieu, resulting in the earlier onset of symptoms relative to other reports.

The major limitation in our report was the unsuccessful vitreous tap. Vitreous taps tend to have positive culture rates of 64% for bacterial endophthalmitis while aqueous taps are lower at 32%.50 Obtaining a vitreous tap would have allowed us greater confidence in ruling out an infectious etiology. Additionally, the patient had a history of zonular dehiscence, which is a risk factor for infectious endophthalmitis and might increase the possibility that this patient may have had endophthalmitis over panuveitis.51

4. Conclusions

This report suggests a possible association between the BNT162b2 booster vaccination and the development of acute panuveitis in the postoperative period after cataract surgery. This condition may mimic acute bacterial postoperative endophthalmitis and may portend a more favorable prognosis, but the authors believe such cases should nonetheless be treated aggressively as presumed infection.

Patient consent

Written informed consent was obtained from the patient for publication of this case report and the accompanying image.

Funding

No funding or grant support.

Acknowledgements

None.

References

1. Office of the commissioner. COVID-19 vaccines. U.S. Food and Drug administration. Published January 7, 2022 https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19-covid-19-vaccines. Accessed January 9, 2022.
2. Menini C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-949.
3. Riad A, Pokorna A, Attia S, Klugaroj K, Kosick M, Kluger M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1428.
4. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589-593.
5. Ng XL, Bezlter BK, Testi I, et al. Ocular adverse events after COVID-19 vaccination. Ocul Immunol Inflamm. 2021;29(6):1-5.
6. Czeg A, Khouri T, Cherfan G, Saad A. Acute corneal endothelial graft rejection following COVID-19 vaccination. J Fr Ophtalmol. 2021;44(8):e445-e447.
7. Phylactou M, Li JP, Larkin DFP. Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine. Ir J Ophthalmol. 2021;55(7):893-896.
8. Wanner LM, Roditi E, Zados D, Berkowizt L, Weill Y. Keratoplasty rejection after the BNT162b2 messenger RNA vaccine. Cornea. 2021;40(8):1070-1072.
9. Renisi G, Lombardi A, Stanzione M, Invernizzi A, Bandera A, Gori A. Anterior uveitis onset after BNT162b2 vaccination: is this just a coincidence? Int J Infect Dis. 2021;110:95-97.
10. Mudie L, Zick JD, Dacey MS, Palestine AG. Panuveitis following vaccination for COVID-19. Ocul Immunol Inflamm. 2021;29(4):741-742.
11. Papasavvas I, Herbert Jr CP. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination. J Ophthalmic Infect Inflamm. 2021;11(1):21.
12. Kalinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T, et al. Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV2 infection: a possible association. Rena. 2021;41(12):2462-2471.
13. Fowler N, Mendez Martinez NR, Pallares BV, Maldonado RS. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine. Am J Ophthalmol Case Rep. 2021;23, 101136.
14. Reyes-Capo DP, Stevens SM, Cavuto KM. Acute abducens nerve palsy following COVID-19 vaccination. J AAPOS. 2021;25(3):302-303.
15. Alamer E, Alhaumi A, Qasir NA, et al. Side effects of COVID-19 Pfizer-BioNTech mRNA vaccine in children aged 12-18 years in Saudi Arabia. Vaccines (Basel). 2021;9(11). https://doi.org/10.3390/vaccines9111229.
16. Andreuzczak-Grzudko S, Crudy Z, Donderska M. Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci. 2021;25(12):4418-4421.
17. Zahid MN. Unfolding the mild to moderate short-term side effects of four COVID-19 vaccines used in Bahrain: a cross-sectional study. Vaccines (Basel). 2021;9(11):1369.
18. ACIP June 2021 presentation slides. Published November 23, 2021 https://www.cdc.gov/vaccines/acip/meetings/slides/2021.06.html. Accessed January 9, 2022.
19. Das BB, Morkowitk WB, Taylor MB, Palmer A. Myocarditis and pericarditis following mRNA COVID-19 vaccination: what do we know so far? Children. 2021;8(7):607.
20. Ammirati E, Cavalioti G, Milazzo A, et al. Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection. Int J Cardiol Heart Vasc. 2021;34, 100774.
21. Friling E, Lundstrom M, Stenevi U, Montan P. Six-year incidence of endophthalmitis after cataract surgery Swedish national study. J Cataract Refract Surg. 2015;39(1):15-21.
22. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol. 1995;113(12):1479-1496.
23. Kangas TA, Greenfield DS, Flynn Jr HW, Parrish 2nd RK, Palmberg P. Delayed-onset endophthalmitis associated with conjunctival filtering blebs. Ophthalmol. 1997;104(5):746-752.
24. Benage M, Fraunfelder FW. Vaccine-associated uveitis. Mo Med. 2016;113(1):48-52.
25. Cunningham Jr ET, Moorthy RS, Fraunfelder FW, Ziherl M. Vaccine-associated uveitis. Ocul Immunol Inflamm. 2019;27(4):517-520.
26. Ng CC, Jumper JM, Cunningham Jr ET. Multiple evanescent white dot syndrome following influenza immunization - a multimodal imaging study. Am J Ophthalmal Case Rep. 2020;19, 100845.
The role of interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019;9(1):17.

Yamaguchi T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology. 2005;44(6):736–741.

Carreño E, Portero A, Herreras JM, et al. Cytokine and chemokine tear levels in patients with uveitis. Acta Ophthalmol. 2017;95(5):e405–e414.

Perez VL, Papaliolidis GN, Chu D, Anzaar F, Christen W, Foster CS. Elevated levels of interleukin-6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12(3):193–201.

Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology. 2009;48(4):347–354.

Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019;9(1):17.

Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci. 2007;48(7):3246–3252.

Lindstedt EW, Baarsma GS, Kuijpers RWAM, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89(5):533–536.

Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60(6):575–589.

Smith 2nd JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol. 1992;10(7):1141–1152.

Conti P, Caraffa A, Gallenga CE, et al. IL-1 induces thromboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J Biol Regul Homeost Agents. 2020;34(5):1623–1627.

Conti B, Tabarran I, Andrei C, Bartfai T. Cytokines and fever. Front Biosci. 2004;9:1433–1449.

Martelletti P. Proinflammatory pathways in cervicogenic headache. Clin Exp Rheumatol. 2000;18(2 Suppl 19):S33–S38.

4. 28. Bergamaschi C, Terpos E, Rosati M, et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021;36(6), 109504.

29. Verma MJ, Lloyd A, Rager H, et al. Chemokines in acute anterior uveitis. Curr Eye Res. 1997;16(12):1292–1298.

30. Abu El-Asrar AM, Struyf S, Descamps FJ, et al. Chemokines and gelatinases in the aqueous humor of patients with active uveitis. Am J Ophthalmol. 2004;138(3):401–411.

31. Carreño E, Portero A, Herreras JM, et al. Cytokine and chemokine tear levels in patients with uveitis. Acta Ophthalmol. 2017;95(5):e405–e414.

32. Perez VL, Papaliolidis GN, Chu D, Anzaar F, Christen W, Foster CS. Elevated levels of interleukin-6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye & ear experience and review of previous studies. Ocul Immunol Inflamm. 2004;12(3):193–201.

33. Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology. 2009;48(4):347–354.

34. Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. J Ophthalmic Inflamm Infect. 2019;9(1):17.

35. Sugita S, Takase H, Taguchi C, Mochizuki M. The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci. 2007;48(7):3246–3252.

36. Lindstedt EW, Baarsma GS, Kuijpers RWAM, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89(5):533–536.

37. Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60(6):575–589.

38. Smith 2nd JW, Urba WJ, Curti BD, et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol. 1992;10(7):1141–1152.

39. Conti P, Caraffa A, Gallenga CE, et al. IL-1 induces thromboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J Biol Regul Homeost Agents. 2020;34(5):1623–1627.

40. Conti B, Tabarran I, Andrei C, Bartfai T. Cytokines and fever. Front Biosci. 2004;9:1433–1449.

41. Martelletti P. Proinflammatory pathways in cervicogenic headache. Clin Exp Rheumatol. 2000;18(2 Suppl 19):S33–S38.

42. Della Vedova C, Cathcart S, Dohmeneck A, et al. Peripheral interleukin-16 levels are elevated in chronic tension-type headache patients. Pain Res Manag. 2013;18(6):301–306.

43. Wan CK, He C, Sun L, Egwuagu CE, Leonard WJ. Cutting edge: IL-1 receptor signaling is critical for the development of autoimmune uveitis. J Immunol. 2016;196(2):543–546.

44. Fabiani C, Sota J, Tosi GM, et al. The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clin Rheumatol. 2017;36(10):2307–2318.

45. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–652.

46. ElSheikh RH, Hasseb A, Elewa TK, Elhusseiny AM. Acute uveitis following COVID-19 vaccination. Ocul Immunol Inflamm. 2021;29(6):1207–1209.

47. El-Harrazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12(1):1–8.

48. Apple DJ, Solomon KD, Tetz MR, et al. Posterior capsule opacification. Surv Ophthalmol. 1992;37(2):73–116.

49. Miyake K, Maekubo K, Miyake Y, Nishi O. Pupillary fibrin membrane. A frequent early complication after posterior chamber lens implantation in Japan. Ophthalmol. 1989;96(8):1228–1233.

50. Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123(2):186–192.

51. Miyake K, Sugiyama S, Norimatsu I, Ozawa T. Prevention of cystoid macular edema after lens extraction by topical indomethacin (III) radioimmunoassay measurement of prostaglandins in the aqueous during and after lens extraction procedures. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978;209(2):83–88.

52. Sjoholm-Gomez de Liano C, Soberon-Ventura VF, Salcedo-Villanueva G, et al. Prevention of cystoid macular edema after lens extraction by topical indomethacin (III) radioimmunoassay measurement of prostaglandins in the aqueous during and after lens extraction procedures. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978;209(2):83–88.

53. Sjoholm-Gomez de Liano C, Soberon-Ventura VF, Salcedo-Villanueva G, et al. Sensitivity, specificity and predictive values of anterior chamber tap in cases of bacterial endophthalmitis. Eye Vis (Lond). 2017;4:18.

54. Rathee VM, Sharma S, Das T, Khanna RC. Endophthalmitis prophylaxis study. Report 1: intracameral cefoxaxime and moxifloxacin prophylaxis for the prevention of postcataract endophthalmitis in rural India. Indian J Ophthalmol. 2020;68(5):819–824.